Development of Anti-VEGF Therapies for Intraocular Use: A Guide for Clinicians
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Angiogenesis is the process by which new blood vessels form from existing vessel networks. In the past three decades, significant progress has been made in our understanding of angiogenesis; progress driven in large part by the increasing realization that blood vessel growth can promote or facilitate disease. By the early 1990s, it had become clear that the recently discovered “vascular endothelial growth factor” (VEGF) was a powerful mediator of angiogenesis. As a result, several groups targeted this molecule as a potential mediator of retinal ischemia-induced neovascularization in disorders such as diabetic retinopathy and retinal vein occlusion. Around this time, it also became clear that increased intraocular VEGF production was not limited to ischemic retinal diseases but was also a feature of choroidal vascular diseases such as neovascular age-related macular degeneration (AMD). Thus, a new therapeutic era emerged, utilizing VEGF blockade for the management of chorioretinal diseases characterized by vascular hyperpermeability and/or neovascularization. In this review, we provide a guide for clinicians on the development of anti-VEGF therapies for intraocular use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522 · cited 2×
“In 2006, ranibizumab was licensed for use in the United States following publication of the MARINA and ANCHOR studies [79, 80].”
BackgroundMethodRanibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Angiogenesis as a therapeutic target
Ferrara, N., & Kerbel, R. S. (2005) · Nature · doi:10.1038/nature04483 · Cited by 2,653 · cited 1×
“Thus, despite the complexity of the angiogenic process, and the potential redundancy of the growth factors involved, VEGF blockade was quickly recognized as a promising approach for the restriction of blood vessel formation in a variety of pathologic scenarios [8].”
BackgroundPegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337 · cited 2×
“In 2004, following publication of results from two, concurrent, phase III clinical trials (the VEGF Inhibition Study in Ocular Neovascularization, or VISION, trials), pegaptanib was licensed for use in the USA by the Food and Drug Administration (FDA) [55].”
BackgroundVEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691 · cited 2×
“VEGF Trap was first described in 2002 [92].”
BackgroundSignal transduction to hypoxia-inducible factor 1
Semenza, G. L. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)01168-1 · Cited by 860
Liu, L., Ammar, D. A., Ross, L. A., Mandava, N., Kahook, M. Y., & Carpenter, J. F. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6431 · Cited by 199 · cited 1×
“Studies have demonstrated differences in bevacizumab concentration and the presence of particulate contaminants following this process, emphasizing the need for implementation of optimal protocols when compounding pharmacies prepare this drug for intravitreal use [58, 68].”
BackgroundNork, T. M. (2011) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2011.210 · Cited by 48
Cited by
Courtaut, F., Aires, V., Acar, N., Bretillon, L., Guerrera, I. C., Chhuon, C., Pais de Barros, J.-P., Olmiere, C., & Delmas, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011023 · Cited by 21
“) [2], treatment failure still occurs due to side effects and resistance.”
BackgroundCourtaut, F., Scagliarini, A., Aires, V., Cornebise, C., Pais de Barros, J.-P., Olmiere, C., & Delmas, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126590 · Cited by 17
Rezaie, F., Davami, F., Mansouri, K., Agha Amiri, S., Fazel, R., Mahdian, R., Davoudi, N., Enayati, S., Azizi, M., & Khalaj, V. (2017) · Journal of Applied Microbiology · doi:10.1111/jam.13483 · Cited by 15
“The Fab heavy and light chains are linked together by an interchain disulfide bond (Rothlisberger et al. 2005; Keane and Sadda 2012).”
BackgroundSghaier, R., Perus, M., Cornebise, C., Courtaut, F., Scagliarini, A., Olmiere, C., Aires, V., Hermetet, F., & Delmas, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911704 · Cited by 11
“) [33], treatment failure still occurs due to side effects and resistance.”
Background
Metadata
- Authors
- Keane, P. A., & Sadda, S. R.
- Venue
- Journal of Ophthalmology
- Publisher
- Hindawi Limited
- Published
- 2012
- Volume
- 2012
- Pages
- 1-13
- ISSN
- 2090-004X (ISSN-L)
- 2090-0058
- OpenAlex
- W1999143095
- Cited by
- 51
- References
- 8
- FWCI
- 3.88
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.